氯巴占与大麻二酚辅助治疗Lennox-Gastaut综合征新进展

Advances in the Adjunctive Treatment of Lennox-Gastaut Syndrome with Clobazam and Cannabidiol

摘要: Lennox-Gastaut综合征(LGS)是一种严重的癫痫性脑病。近年来，已有多种药物被批准用于治疗LGS。美国食品药品监督管理局分别于2011年10月和2018年6月批准了氯巴占、大麻二酚辅助治疗LGS。本文从氯巴占和大麻二酚的化学结构、药理作用、疗效、安全性、药物相互作用等方面进行综述，以介绍两种药物的研究现状和已有成果。

Abstract: Lennox-Gastaut syndrome (LGS) is a severe, epileptic encephalopathy.In recent years, a variety of drugs have been approved for the treatment of LGS. The U.S. Food and Drug Administration approved clobazam and cannabidiol as adjunctive therapy for LGS in October 2011 and June 2018, respectively. This article provides an overview of clobazam and cannabidiol, including their chemical structures, pharmacological actions, curative effects, safety profile, drug interactions, to introduce the current state of research and the achievements of both drugs.